7 2019 INTEGRATED SUMMARY REPORT SCIENCE OVERVIEW Speed Life-Changing Medicines Lilly has always pushed the boundaries of science in order to caused by specific gene mutations. One of these new medicines, make conditions that are incurable today, treatable tomorrow. selpercatinib, has been submitted to regulators for approval to treat In 2019, we received regulatory approval for two new medicines – medullary thyroid cancers and non-small cell lung cancer and Baqsimi, which launched last year, and Reyvow, which launched received U.S. priority review designation. this year. We’ve brought 11 new therapies to patients since 2014 With technology partner Strateos, we opened a first-of-its-kind, and expect to introduce nine more by the end of 2023, achieving robotic laboratory in San Diego. The Lilly Life Sciences Studio our goal of 20 new medicines in 10 years. physically and virtually integrates several areas of the drug Our pipeline continues to be cited as one of the most promising discovery process together into a fully automated platform. The lab in the industry across our core therapeutic areas of diabetes, enables research scientists to remotely control their experiments via oncology, immunology, pain and neurodegeneration. We’re moving a web-based interface. This technology was designed to decrease medicines to patients faster. The number of molecules starting the amount of time it takes scientists to receive critical data, thus clinical trials in 2019 rose by nearly 50% versus the previous year. accelerating the drug discovery process. To accomplish this, we’re using creative methods to access Lilly created a new shared innovation lab in South San Francisco, innovation – investing in advanced technologies and looking designed to speed the discovery of innovative medicines through beyond our walls for emerging scientific ideas. collaboration with other biotech companies. Lilly Gateway Labs An example of this new thinking is how we approach early phase provides companies the potential opportunity to collaborate with oncology research. We created Loxo Oncology at Lilly, a combined Lilly on projects of mutual interest and exposure to Lilly’s scientific organization that marries the speed and agility of Loxo with the and drug development expertise. They also have the potential for scale and capabilities of Lilly. We acquired Loxo Oncology in 2019, financial investment from Lilly, venture funds or both. adding potential medicines tailored for patients with cancers New Medicines for Patients Global Launches Potential Launches 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Trulicity® Basaglar® Taltz® Verzenio® Emgality® Baqsimi™ Reyvow™ Tanezumab Tirzepatide BTK Inhibitor Jardiance® Portrazza® Olumiant® Ultra-Rapid Mirikizumab Lebrikizumab Cyramza® Lispro (IL-13 mAb) Selpercatinib Automated Insulin Delivery System RET Inhibitor Effort 2